2235-99-6 Usage
General Description
Guanidine, (2-phenylethyl)-, monohydrochloride is a chemical compound with notable applications in various fields. Guanidine, (2-phenylethyl)-, monohydrochloride, commonly referred to as phenylethylguanidine hydrochloride, features a guanidine moiety attached to a phenylethyl group and a hydrochloride counterion. It finds utility in organic synthesis as a versatile reagent, particularly in the production of pharmaceuticals and agrochemicals due to its ability to facilitate numerous synthetic transformations. Additionally, it exhibits pharmacological properties, showing promise in research related to neurotransmission modulation, ion channel function, and potential therapeutic interventions for neurological disorders. Furthermore, its physiological effects are of interest in biomedical research, where it is studied for its impact on various biological processes, including muscle contraction and neurotransmitter release.
Check Digit Verification of cas no
The CAS Registry Mumber 2235-99-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,2,3 and 5 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 2235-99:
(6*2)+(5*2)+(4*3)+(3*5)+(2*9)+(1*9)=76
76 % 10 = 6
So 2235-99-6 is a valid CAS Registry Number.
2235-99-6Relevant articles and documents
Simple generalized reaction conditions for the conversion of primary aliphatic amines to surfactant-like guanidine salts with 1H-pyrazole carboxamidine hydrochloride
Bakka,Gautun
, p. 169 - 172 (2017)
Improved reaction conditions for the electrophilic reaction between a free aliphatic amine and 1H-pyrazole carboxamidine have been discovered. The surfactant-like guanidine salts, which are often hard to work with, were obtained in decent yields with short reaction times, minimal workup, and high level of purity.
GUANIDINE COMPOUNDS AND USE THEREOF
-
Page/Page column 72; 73, (2015/11/09)
The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
